Alternatives to Pando Bioscience

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

AI-driven scientific diligence software for pharma BD, biotech and life science investors evaluating in-licensing, M&A and investment

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

NExTNet pairs an evidence-backed life sciences Copilot with Explorer knowledge maps over a deterministic biomedical ontology.

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

Physics-based molecular simulation with AI for drug discovery and materials design.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Xaira Therapeutics pairs causal AI perturbation models X-Cell and X-Design with agentic and robotic labs to find, design, and validate new

AI-first biotech pairing Proton's machine-learning medicinal chemistry with synthesis-aware molecule design.

AI evidence assembly and quantitative modeling for clinical pharmacology — MBMA databases, Project Optimus dose work, exposure-response

Cellbyte is the AI workspace where pharma Pricing & Market Access teams get source-linked HTA and pricing answers in minutes.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Infera compiles written lab protocols into validated, instrument-ready liquid-handler runs.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.